R egulatory T cells (T reg cells) are a specialized suppressive CD4
+ T cell population capable of limiting deleterious immune responses to self and foreign antigens that underlie autoimmune and chronic inflammation 1, 2 . Conversely, T reg cells suppress beneficial anti-tumor immunity and thereby pose an impediment to effective immunotherapies 3, 4 . Indeed, increased frequencies of T reg cells and a reduced CD8 + /T reg cell ratio in tumors are linked to poor prognosis in many cancers 3, 5 . Although T reg cell depletion dramatically reduces tumor burden, the ensuing autoimmune sequelae limit the use of this approach in the clinic 6, 7 . Hence, current trials are evaluating strategies targeting receptors preferentially enriched on intratumoral T reg cells (CCR4, GITR, OX40, CTLA4) 8 . T reg cells use a plethora of suppressive mechanisms-inhibitory cytokine secretion, metabolic disruption, modulation of antigen-presenting cell function and cytolysis of effector cells-often in a target cell and tissue-specific manner 1 . While targeting suppressive mechanisms selectively used by intratumoral T reg cells would be efficacious, the precise mechanisms and predominant suppressive mediators that promote T cell exhaustion and dominant suppression in the tumor microenvironment (TME) remain poorly defined.
One of the major contact-independent modes of T reg cell suppression is via secretion of inhibitory cytokines (IL-10, IL-35 and TGF-β) 1, 9 . The established suppressive cytokine duo (IL-10 and TGF-β) plays a critical role in steady-state immune homeostasis and taming exuberant responses at environmental interfaces. Perturbation of IL-10 and TGF-β signaling improved the function of exhausted T cells in chronic viral infections [10] [11] [12] . Co-targeting T reg cells or IL-10 along with the PD-1 immune checkpoint pathway resulted in a synergistic reversal of T cell exhaustion 13, 14 . IL-35 is required for maximal T reg cell suppressor function and contributes to the regulatory milieu in numerous disease states 15, 16 . Previous work demonstrated enrichment of IL-35 expression on tumor-infiltrating T reg cells in B16 tumors and a role of IL-35 in promoting inhibitory receptor expression (PD-1, TIM3, LAG3) on intratumoral T cells 7 . Thus, while T reg cells and suppressive cytokines have been linked to T cell exhaustion in chronic settings, the molecular mechanisms and the relative contribution of T reg cell-derived suppressive cytokines underlying T reg cell-induced exhaustion remain obscure.
In this study, we report a divergent and largely non-overlapping IL-10 and IL-35 expression pattern on T reg cells infiltrating both murine tumors as well as patients with non-small cell lung cancer (NSCLC). We further demonstrate that these IL-10 + and Ebi3 + T reg cell populations are not distinct lineages, but rather transitory states with concordant transcriptional and T cell receptor (TCR) profiles. This transition is inducible via TCR stimulation of purified T reg cell subpopulations in vitro, potentially reflecting plasticity in inhibitory cytokine expression in chronic environments. While the two cytokines target a common BLIMP1 axis to promote the exhausted Articles NaTuRE IMMuNOLOgy intratumoral T cell state, IL-10 and IL-35 differentially impacted effector versus memory generation, respectively. Our results uncover the previously unappreciated adaptive plasticity of IL-10 and IL-35 inhibitory cytokine expression by T reg cell subpopulations in the TME and how they cooperatively impinge on T cell function to promote exhaustion and limit anti-tumor immunity.
Results
Divergent IL-10 and IL-35 expression on T reg cells in murine tumors and NSCLC patients. Intratumoral T reg cells are more suppressive than their peripheral counterparts in both murine models and human tumors owing to their heightened activation status 3, 4 . Thus, we reasoned that the major suppressive mediators might be co-expressed on intratumoral Foxp3
+ T reg cells to maximize their functional impact. To address this hypothesis, we generated triple reporter mice (Il10 GFP
Tom .Foxp3 Cre-YFP ; Il10 for IL-10, Ebi3 for IL-35 and Foxp3 for T reg cells, respectively 7, 17, 18 ; Fig. 1a and Supplementary Fig. 1a ). We observed largely segregated expression of IL-10 and Ebi3 by T reg cells in various lymphoid and nonlymphoid organs, with minimal co-expression ( Supplementary  Fig. 1b ), consistent with a previous report 19 . The only tissues with a notable (>5%) population of T reg cells co-expressing IL-10 and Ebi3 at steady state were skin and lamina propria, probably due to elevated IL-10 + T reg cells at these environmental interfaces ( Supplementary Fig. 1b ). Specifically, in the B16 TME, there was an approximately four-and two-fold intratumoral enrichment of IL-10 + (GFP + YFP + ) and Ebi3 + (Tom + YFP + ) T reg cells, respectively, compared to the periphery (Fig. 1a-c) .
Furthermore, this divergent inhibitory cytokine distribution in T reg cells was not a characteristic limited to the T H 1-polarized TME, as we noted a similarly divergent expression pattern in a T H 2-polarized fungal protease (Aspergillus oryzae) model of allergic airway disease (Fig. 1d-f ) 20 . The enrichment of IL-10 + T reg cells was more pronounced in the allergic environment than the B16 TME, resulting in an approximately ten-fold expansion compared to the periphery, supporting the notion of adaptive plasticity in the relative abundance of IL-10 + and IL-35 + T reg subpopulations depending on the nature of the inflammatory microenvironment. T reg cellrestricted deletion of Ebi3 in Il10 Cre-YFP mice did not result in a compensatory change in the distribution of these T reg cell subpopulations in either T H 1-or T H 2-polarized inflammatory environment ( Supplementary Fig. 1c-h ). Human T reg cells from healthy donors and NSCLC patients also showed a similar segregated IL-10 and IL-35 expression pattern with a minimal percentage of double cytokine positive T reg cells (Fig. 1g-i) . In this case, there was also an increased percentage of Ebi3 + intratumoral T reg cells, highlighting the translational importance of understanding the developmental and functional relationship between these intratumoral T reg cell subpopulations. Collectively, these data highlight preferential enrichment and divergent inhibitory cytokine expression pattern on mouse and human intratumoral T reg cells.
Adaptive plasticity of cytokine expression and comparable transcriptome of intratumoral IL-10
+ and IL-35 + T reg cell subpopulations. To dissect the divergent cytokine expression pattern and the preferential generation of single inhibitory cytokine positive T reg cell subpopulations, we performed single-cell RNAseq (scRNAseq) comparing T reg cells isolated from naive, unchallenged lymph nodes or day 14 B16 tumors from Foxp3
Cre-YFP mice (Fig. 2a) . IL-10 + and Ebi3 + T reg cells exhibited comparable transcriptomic signatures (Fig. 2b,c) . Although unsupervised K-means clustering identified six unique T reg cell clusters ( Supplementary Fig. 2a ), the distribution ratio of IL-10 + versus Ebi3 + T reg cell subpopulations among those clusters was comparable, especially for intratumoral T reg cells (Supplementary Fig. 2b ). Consistent with the scRNAseq analyses, T cell receptor beta chain (TCRβ)-sequencing of IL-10 + and Ebi3 Fig. 2c ). We did not observe any bias in TCR V β -gene usage or CDR3-length, which can play a role in regulating T cell development and differentiation via TCR affinity and signaling strength 21, 22 ( Fig. 2d and Supplementary Fig. 2d ). Furthermore, substantial TCR clonal overlap noted among intratumoral T reg cell subpopulations is consistent with the lack of distinct transcriptomic signatures ( Supplementary  Fig. 2e ). TCR signaling plays a crucial role in the production of both IL-10 and IL-35 (ref. 23 ). We noted that TCR stimulation in vitro was sufficient to induce Il10 and Ebi3 expression in purified T reg cell subpopulations (Fig. 2e) , inferring extensive developmental plasticity. There was a preferential upregulation of Ebi3 expression observed during in vitro fate mapping, which is consistent with a progressive enrichment of Ebi3 + (either IL-10 -Ebi3 + or IL-10 + Ebi3 + ) T reg cells revealed by diffusion pseudo-time analysis (Fig. 2f,g ). Furthermore, while it has been reported that the development and function of Ebi3 + T reg cells are independent of BLIMP1 expression 19 , our results indicate that BLIMP1 may also play a key role in supporting the maintenance and function of Ebi3 + T reg cells as approximately 90% of TIL T reg cells express BLIMP1 and 30-50% of which are Ebi3 + ( Supplementary Fig. 2f and Fig. 1a-c ). These observations suggest that TCR signaling, and perhaps the suppressive tumor milieu, might drive this adaptive plasticity and lead to the generation of T reg cell subpopulations marked by transitory IL-10 and IL-35 expression.
We also performed bulk RNAseq-based transcriptome analysis on purified LN and tumor (TIL) T reg cell subpopulations defined by Il10 and Ebi3 reporter expression ( Supplementary Fig. 3a) , to further investigate the transcriptomic relationship between these T reg cell subpopulations with greater sequencing depth. Principal component analysis (PCA) of differentially regulated genes clearly separated lymph node versus TIL T reg cells, irrespective of cytokine expression pattern ( Supplementary Fig. 3a) . Consistent with the scRNAseq data, bulk profiling revealed no striking transcriptomic differences between intratumoral T reg cell subpopulations ( Supplementary Fig. 3b ). Modest differences were noted in expression patterns of genes encoding co-signaling molecules (Cd226, Tnfsf11, Cd2, Lag3, Cd27, Cd28), probably reflecting their relative suppressive capacity noted in vitro ( Supplementary Fig. 3c-f) . Collectively, the concordant transcriptional and TCR profiles highlight these IL-10 + and Ebi3 + T reg cell subpopulations as plastic transitory states, rather than distinct subsets.
Cooperative regulation of anti-tumor immunity by IL-10
+ and IL-35 + T reg cells. It was previously shown that mice with a T reg cellrestricted Ebi3 deletion, and thus loss of IL-35 production, exhibit reduced tumor burden 7 . To assess the functional impact of IL-10-and IL-35-producing T reg cell subpopulations on the TME, we compared the growth rate of three transplantable tumor models; B16 and BrafPten (clone 24) melanoma models and EL4 thymoma in mice with T reg cells that are unable to produce IL-10 (Il10
Cre-YFP ). T reg cell-restricted deletion of Il10 or Ebi3 resulted in a comparable reduction in tumor growth (Fig. 3a-c) . Dualdeletion did not exhibit a significant additive or synergistic reduction in tumor burden in both the melanoma models and only a marginal effect on EL4, suggesting that T reg cell-derived IL-10 and IL-35 might regulate anti-tumor immunity through a common, cooperative pathway. 
Cre-YFP ) demonstrated a near complete loss of the PD-1 hi and multi-inhibitory receptor + populations and significant enrichment of inhibitory receptor-negative CD8 + T cells (Fig. 3d ,e and Supplementary Fig. 4a,b) . B16 TIL analysis at a later time point (day 20) revealed a less extensive reduction of inhibitory receptor expression on CD8
Cre-YFP mice, while CD8
Cre-YFP mice still exhibited diminished inhibitory receptor expression ( Supplementary Fig. 4c,d ). Although the overall extent of PD-1 hi and multi-inhibitory receptor expression was not as prominent on CD4 + TILs, T reg cell-restricted deletion of Il10 and Ebi3 showed a comparable, substantial impact on PD-1 hi multi-inhibitory receptor + CD4 + TILs at both time points as their CD8 + counterparts (Fig. 3f,g and Supplementary Fig. 4e,f) . These data suggest that while both T reg cell-derived IL-10 and IL-35 function cooperatively in driving inhibitory receptor induction on TILs, IL-35 may play a more dominant role.
We also analyzed the impact of inhibitory cytokine-driven multi-inhibitory receptor induction on CD8 + T cell differentiation as well as other cell types in the TME. Increased cellularity and cytokine production were noted in tumors of Il10
Cre-YFP mice (Fig. 4a,b and Supplementary Fig. 5a,b) , while enhanced T CM differentiation was noted in both Ebi3
Cre-YFP and Il10
Cre-YFP TMEs (Fig. 4c) . We also examined myeloid Cre-YFP mice, which conversely was decreased in Ebi3
Cre-YFP mice (Supplementary Fig. 5f ) 24, 25 . Collectively, these data point to the differential impact of T reg cellrestricted deletion of these two cytokines on the TME, with an apparent greater impact of IL-10 in limiting effector function and proliferation, whereas IL-35 seems to limit memory differentiation.
T reg cell-derived IL-35 and IL-10 can directly induce inhibitory receptor expression on intratumoral CD8
+ T cells. We next investigated whether IL-10 and IL-35 were directly impacting CD8 + T cells in the TME or if this regulation required an intermediate or accessory cell. We created an experimental system in which only CD8 + T cells were unable to respond to IL-10 or IL-35 using a Rag1
-/-reconstitution model ( 
TIM3
-SP, (3) PD-1 int and (4) PD-1 neg T cell subsets ( Fig. 6a and Supplementary Fig. 6a ). PCA of these subsets from control Foxp3
Cre-YFP mice segregated them into defined clusters on the basis of location (NDLN versus TIL) and state of exhaustion (NEG, INT, SP versus DP), highlighting the distinct transcriptional signatures specific to each subset (Fig. 6a,b) . Differential gene expression analysis comparing the CD8 + TIL subsets from single and dual T reg cell cytokine-deficient mice to corresponding wild-type counterparts revealed that the alteration of the TME by T reg cell-restricted deletion of IL-10 and/or IL-35 influenced the transcriptome of all the CD8 + subsets (Supplementary Fig. 6b-d ). In particular, gene set enrichment analysis (GSEA) confirmed significant downregulation of an exhaustion signature in SP and DP CD8
+ subsets from Il10
Cre-YFP mice, relative to the control CD8 + T cells (Fig. 6c ). This exhaustion gene signature of CD8
+ TIL subsets displayed strong congruence to the published data from LCMV infection 28 , indicative of a core molecular program that drives PD-1 int to PD-1 hi transition in chronic settings ( Supplementary Fig. 6e ). These results further support the ability of both IL-10 + and IL-35 + T reg cell subpopulations to drive the PD-1 int to PD-1 hi transition thereby promoting the multiinhibitory receptor + TIL state (Fig. 6c ). We next interrogated the transcription factors that were upregulated during the PD-1 int to PD-1 hi transition in control CD8 + T cells and assessed their expression in mice lacking IL-10 and/or IL-35 in T reg cells. The transcription factor Prdm1 (encoding BLIMP1) was one of the top genes induced during this transition and was significantly reduced in SP and DP CD8
Cre-YFP mice ( Fig. 6d ). Reduced Prdm1 expression was accompanied by an upregulation of its target genes (many of which are characteristic of memory T cells: Tcf7, Id3, Il7r) 29 ( Fig. 6d-g ), which is in agreement with an increase in CD8
+ central memory T cells (T CM ) (Fig. 4c) . We also noted upregulation of a PD-1 blockade-responsive TCF-1
Cre-YFP mice ( Supplementary Fig. 6f ). Collectively, these data suggest common modulation of the BLIMP1 axis by the T reg cell-derived IL-10 and IL-35 for optimal induction of an exhaustion gene signature in intratumoral CD8
+ T cells.
Direct regulation of BLIMP1 locus by T reg cell-derived IL-10 and IL-35.
BLIMP1 is a well-characterized regulator of terminal differentiation for both T and B cell lineages, and it has been reported to drive inhibitory receptor expression and exhaustion of CD8 + T cells in chronic viral infection 31 . However, its role in intratumoral T cell exhaustion and whether it links T reg cell-derived cytokines with inhibitory receptor expression is unknown. Analysis of B16 tumorbearing Prdm1
YFP reporter mice revealed that BLIMP1 expression was strongly correlated with PD-1 hi and multi-inhibitory receptor + CD8 + TILs ( Supplementary Fig. 7a -c) and BLIMP1 protein 
Cre-YFP mice inoculated with 1.25 × 10 5 tumor cells intradermally: (a) B16 (**P = 0.0019, ***P = 0.0004, ****P < 0.0001); (b) BrafPten clone 24 (*P = 0.0263, ****P < 0.0001); (c) EL4 ( # P = 0.0054, *P = 0.0047, **P = 0.0043, ***P = 0.0003, ****P < 0.0001). Data averaged from three independent experiments with an indicated total number of mice per genotype. Each measurement time point represents a mean value with an s.e.m. error bar. Statistical significance was determined by two-way ANOVA with Holm-Sidak multiple comparisons. d, Representative flow plots depicting the expression of inhibitory receptors (PD-1 versus other inhibitory receptors: TIM3, LAG3, TIGIT and 2B4) on CD8 + T cells infiltrating d14 B16 tumor-bearing Foxp3
Cre-YFP (n = 13), Il10
Cre-YFP (n = 10) mice. SPICE plots depicting the co-expression of inhibitory receptors. e, Scatter-bar graphs tabulating the percent distribution of inhibitory receptor-negative (0 and 1 inhibitory receptor-expressing effector-like) and multi-inhibitory receptor + (3-5 inhibitory receptor-expressing exhausted) CD8 + TILs as in d. Bars represent mean values. Statistical significance was determined by one-way ANOVA with Holm-Sidak multiple comparisons (****P < 0.0001 and other P values indicated). f, Representative flow plots depicting expression of inhibitory receptors (PD-1 versus the other inhibitory receptors -TIM3, LAG3, TIGIT and 2B4) on CD4
Cre-YFP (n = 10) mice. SPICE plots depicting expression and co-expression of several inhibitory receptors on CD4 + Foxp3 -TILs. g, Scatterbar graphs representing the percent distribution of inhibitory receptor-negative (0 and 1 inhibitory receptor-expressing effector-like) and multi-inhibitory receptor + (3-5 inhibitory receptor-expressing exhausted) CD4 Articles NaTuRE IMMuNOLOgy was significantly reduced in the TME that lacks T reg cell-derived IL-10 or IL-35 ( Supplementary Fig. 7d ). Adoptively transferred OT-I.Prdm1
YFP transgenic CD8
Cre-YFP mice compared to Foxp3
Cre-YFP counterparts, further corroborating the role of both T reg cell-derived IL-10 and IL-35 to cooperatively promote the intratumoral multi-inhibitory receptor + TIL state via BLIMP1 induction (Fig. 7a-c) .
We next assessed inhibitory receptor expression in mice with a CD8 
Inhibitory receptors (indicated on top) 
Inhibitory receptors (indicated on top) No.
Ebi3 L/L-Tom . 
Cre-YFP (9) Articles NaTuRE IMMuNOLOgy CD8 + TILs, mirroring our observations in T reg cell-mutant mice, while heterozygous Prdm1
CreGFP mice exhibited a substantive but intermediate inhibitory receptor reduction ( Fig. 7d and Supplementary Fig. 7e ). Consistent with the T reg cell cytokinedeficient mice, expression of memory-associated genes (IL-7R and TCF-1) were also upregulated in Prdm1
CreGFP mice (Fig. 7e) . It has been reported previously that bi-allelic deletion of BLIMP1 results in a loss of effector functions in CD8 + T cells in the context of chronic viral infection despite diminished inhibitory receptor expression 32 . Indeed, no loss of tumor growth was observed in Prdm1
CreGFP mice (Fig. 7f) . Induced BLIMP1 haploinsufficiency 32 or double-deletion of BLIMP1 and c-Maf 33 in CD8 + T cells was required to reinvigorate the cytotoxic effector function and memory-potential, as c-Maf is highly upregulated in the absence of BLIMP1 and is capable of regulating a largely overlapping network of genes, maintaining the exhausted phenotype 33 . Consistent with these observations, heterozygous Prdm1
CreGFP mice exhibited improved B16 tumor control comparable to T reg cell cytokine-deficient mice (Fig. 7f) .
Finally, ChIP-quantative PCR (qPCR) revealed that IL-10-induced STAT3 (ref. 34 ) and IL-35-induced STAT1 and STAT4 (ref. 26 ) were differentially enriched at STAT-binding sites inside the Prdm1 gene locus (Fig. 7g,h ), suggesting that IL-10 and IL-35 may act directly on CD8 + T cells to modulate the BLIMP1-inhibitory receptor axis. Overall, these data confirm an intrinsic role of BLIMP1 in regulating inhibitory receptor expression of T cells in tumors and validate BLIMP1 as a direct downstream target of both T reg cellderived cytokines, IL-10 and IL-35, in their cooperative promotion of multi-inhibitory receptor expression on TILs ( Supplementary  Fig. 7f ).
Discussion
Collectively, our data support a model in which different subpopulations of intratumoral T reg cells produce IL-10 and IL-35 while exhibiting adaptive plasticity in their cytokine production, which seems to favor single rather than double inhibitory cytokine-secreting states. Although these two inhibitory cytokines cooperatively regulate the BLIMP1-inhibitory receptor axis in CD4 + and CD8
+
TILs and exhibit largely overlapping functions such as induction of an inhibitory receptor module (including PD-1, LAG3, TIM3, TIGIT, 2B4), IL-35 appears to play a greater role in inhibitory receptor induction and limiting T CM differentiation, whereas IL-10 plays a greater role in regulating cytokine production and effector function. Cooperatively, they have a substantive impact on anti-tumor
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Cre-YFP (n = 12) mice) and 20 days (Foxp3
Cre-YFP (n = 10) mice) after B16 tumor inoculation. a-c, Data averaged from three independent experiments. Bars represent mean values. Statistical significance was determined by one-way ANOVA with Holm-Sidak multiple comparisons (****P < 0.0001 and other P values indicated).
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immunity. Loss of T reg cell-derived IL-10 and IL-35 also results in (1) significant downregulation of the exhaustion gene signature, (2) upregulation of a memory-associated transcriptional profile and (3) development of a CXCR5 + signature in CD8 + TILs that is observed following PD-1 checkpoint blockade 30 . These data suggest that IL-10-or IL-35-targeted immunotherapy may have a broader therapeutic impact than previously appreciated.
The physiological requirement for inducible, transitional, divergent intratumoral T reg cell subpopulations that shift between IL-10 and IL-35 single inhibitory cytokine expressing states remains unclear. Adaptive plasticity in T reg cell function has been reported in a number of inflammatory scenarios 2 . While expression of Foxp3 and TCR signaling drive the core suppressive module 23, 35, 36 , T reg cells retain developmental plasticity to adapt to their microenvironment leading to their acquisition of additional suppressive modules characterized by expression of transcription factors, miRNAs, chemokine receptors and suppressive mediators. The current study exemplifies this plasticity in T reg cell fates in the context of the tumor microenvironment, wherein priming in response to tumor antigens and/or the suppressive tumor milieu leads to the generation of IL-10 + and Ebi3 + T reg cells for optimal tumor-induced immune suppression. Reciprocal IL-10 and IL-35 expression on T reg cells has also been reported to play a role in the maintenance of immune tolerance 19 . In this context, differential TCR signal strength led to the generation of distinct effector IL-10 + and IL-35 + T reg cell subsets that function in a complimentary fashion in the control of autoimmunity. In fact, such heterogeneity in inhibitory cytokine expression expands beyond the T reg cell lineage and has also been noted for regulatory plasma cells. During Salmonella enterica Typhimurium infection, different subsets of CD138 hi plasma cells, depending on their maturation level, expressed either IL-10 or IL-35 and very few co-transcribed Il10, Ebi3 and Il12a together 37 . This functional segregation may represent a unifying theme of regulatory cell subsets for maximizing immunoregulation offering a 'last-resort' to subvert beneficial anti-tumor or detrimental autoreactive T cell responses while limiting collateral tissue damage. While the mechanism that limits the accumulation of dual inhibitory cytokine expressing T reg cell subpopulations will require further analysis, it is possible that IL-10 and IL-35 cooperatively limit T reg cell development and expansion in a cell-intrinsic manner limiting the abundance of IL-35/IL-10-dual expressing T reg cells. 
Rag1
-/-+ WT CD8 (n = 11) 
Cre-YFP Gene rank 0 2 ,500 5,000 7,500 10,000 Gene rank 0 2 ,500 5,000 7,500 10,000 
Cre-YFP P = 0.062 P = 0.005
Fig. 6 | T reg cell-derived IL-10 and IL-35 regulate CD8 + TILs through BLIMP1-inhibitory receptor axis. a-e. Data averaged from five independent RNAseq experiments: Foxp3
Cre-
Cre-YFP CD8s (n = 4). a, The gating strategy for double-sorted CD8 Cre-YFP mice; The y axis represents differentially expressed genes in the T reg cell cytokine-deficient environments relative to control Foxp3
Cre-YFP counterparts. Only significantly changed transcription factors are listed. We only considered transcription factors that were differentially expressed in exhausted cells (PD-1 hi , DP and SP) with a minimum log 2 fold change of 1.5, which was further filtered for ones that were differentially expressed across genotypes in the SP subset with the same cutoffs. e, GSEA of the BLIMP1 associated gene signature in SP (left) and DP (right) subsets of Foxp3
Cre-YFP mice; P values as indicated. c,e, Statistical significance was determined by the 'RankSumTestWithCorrelation' test in the limma R package with correction for loss in degrees of freedom due to correlation among genes. All P values are two sided. No correction for multiple hypotheses was performed. f, Representative histograms for validation of BLIMP1 and its associated gene (TCF-1 and IL-7R) at the protein level in the CD8
+
TILs from B16 tumor-bearing Foxp3
Cre-YFP (n = 6), Il10
Cre-YFP (n = 6) mice from two independent experiments. g, Scatter-bar plots tabulating the expression levels of BLIMP1, IL-7R and TCF-1 as in f. Statistical significance was determined by one-way ANOVA with Holm-Sidak multiple comparisons (****P < 0.0001 and other P values as indicated).
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Despite the differential inhibitory cytokine expression pattern, comprehensive profiling of IL-10 + and Ebi3 + T reg cells did not reveal striking transcriptional and TCR differences between these subpopulations. These results differ from previous observations where differences were noted in transcription factor dependency, chemokine receptor expression and activation status of IL-10 + and 
Cre-YFP 
Foxp3
Cre-YFP (n = 6) mice bearing B16-OVA tumors. c, Stacked-bar graphs depicting the BLIMP1 expression in the donor CD8 + T cells as in b. Statistical significance was determined by two-way ANOVA with Holm-Sidak multiple comparisons (****P < 0.0001 and other P values as indicated). d, Representative flow and SPICE plots depicting the expression pattern of inhibitory receptors (PD-1, TIM3, LAG3, TIGIT and 2B4) on CD8 + TILs from B16-tumor-bearing E8I
Cre-GFP (n = 9), Prdm1
.E8I Cre-GFP (n = 10) mice. e, Representative histograms depicting the expression levels of BLIMP1, IL-7R and TCF-7 on CD8 + TILs from B16 tumor-bearing E8I Cre-GFP (n = 8), Prdm1
Cre-GFP (n = 12), Prdm1
.E8I Cre-GFP (n = 6) mice. Scatter plots tabulating the percent distributions (bottom). Statistical significance was determined by one-way ANOVA with Holm-Sidak multiple comparisons (****P < 0.0001 and other P values as indicated). f, Tumor growth curves of E8I
Cre-GFP (n = 20), Prdm1
.E8I Cre-GFP (n = 9) mice inoculated with 1.25 × 10 5 B16 tumor cells intradermally. Data averaged from two independent experiments. Statistical significance was determined by two-way ANOVA with Holm-Sidak multiple comparisons (*P = 0.0165, **P = 0.0008, ***P = 0.0002, ****P < 0.0001). g, Depiction of the locus surrounding mouse Prdm1. The annotated STAT-binding sites were investigated here. h, Chromatin immunoprecipitation (ChIP) analysis of IL-10-mediated STAT3 binding and IL-35-mediated STAT1/STAT4 binding to Prdm1 locus of CD8 + T cells activated for 48 h with anti-CD3, anti-CD28 and rhIL-2, followed by 4 days expansion with rhIL-2, resting in serumfree media for 2 h, then stimulation with IL-10 or IL-35 for 30 mins at 37 o C. Chromatin was immunoprecipitated with anti-STAT1, anti-STAT3, anti-STAT4 or monoclonal rabbit IgG isotype control for real-time PCR analysis. Fold enrichment was calculated on the basis of the isotype controls, which was then normalized to the no-cytokine stimulation (No-Stim.) controls. Data averaged from five independent experiments. Bars represent mean values. Statistical significance was determined by two-way ANOVA with Holm-Sidak multiple comparisons (P values as indicated). NS, not significant.
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IL-35
+ T reg cells isolated from secondary lymphoid organs 19 . In this study, BLIMP1 expression marked the IL-10 + T reg cell subset while IL-35 + T reg cells were predominantly BLIMP1-independent. In contrast, we noted that over 90% of T reg cells express BLIMP1 in B16 tumors, indicating that BLIMP1 may also play a role in regulating the development and function of IL-35 + T reg cells as approximately 30-50% of these intratumoral T reg cells express IL-35. It is conceivable that following priming in response to tumor antigens, the T reg cell repertoire that migrates to the tumor is fixed in its core transcriptional identity, while still retaining plasticity in inhibitory cytokine expression. T reg cell-restricted IL-35 depletion did not lead to a compensatory increase in IL-10 + T reg cells. While we were unable to assess the effect of T reg cell-restricted IL-10 loss on IL-35 + T reg cells, it has been suggested that mice with BLIMP1-deficient T reg cells (unable to produce IL-10) exhibited a two-fold enrichment of IL-35 + T reg cells 19 . Thus, it is possible that if T reg cell-restricted IL-10 deficiency led to a compensatory increase in IL-35 + T reg cells in our B16 tumor model, this may explain several aspects: (1) the less dramatic loss of multi-inhibitory receptor-positive TILs in Il10
Cre-YFP as well as Rag1
-/-reconstitution studies with IL-10R -/-CD8 + T cells, (2) consistent and more dramatic loss of multi-inhibitory receptor
Cre-YFP mice, respectively, and (3) lack of synergy or additivity in B16 tumor control in Il10
Cre-YFP mice. This may in part also underlie the non-overlapping regulation of effector versus memory responses by the two cytokines, with relatively low BLIMP1 protein reduction in Il10
Cre-YFP mice compared to Ebi3
Cre-YFP mice, recapitulating BLIMP1 haploinsufficiency 32 and translating to increased effector responses and decreased memory generation. Although BLIMP1 is well-established as a driver of inhibitory receptor expression, a recent report demonstrated that another transcription factor, c-MAF, sufficiently promoted inhibitory receptor expression in the absence of BLIMP1, by impacting overlapping transcriptional networks. However, our RNAseq dataset did not reveal significant modulation of Maf expression in CD8 + TILs from T reg cell cytokine-deficient mice relative to Foxp3
Cre-YFP counterparts, highlighting specific modulation of the BLIMP1 axis by IL-35 and IL-10 in cooperative regulation of T cell exhaustion.
In summary, the adaptive plasticity and cooperative regulation of anti-tumor immunity by IL-10 + and IL-35 + T reg cells pose another tumor-immune evasive strategy and potential resistance mechanism to immunotherapy. Understanding this complex T reg cell-driven regulatory circuitry in the TME may inform the rational design of combinatorial modalities targeting T reg cells and their downstream mediators that promote T cell exhaustion to maximize responsiveness to checkpoint blockade and other immunotherapies while limiting adverse events and the risk of inflammatory or autoimmune complications.
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Articles NaTuRE IMMuNOLOgy Methods Mice. Unless otherwise specified, all experimental procedures were performed on 5-8 week-old laboratory mice housed in Helicobacter/MNV free SPF facilities at the University of Pittsburgh in accordance with the current National Institutes of Health guidelines and with the approval and guideline of the Institutional Animal Care and Use Committee of the University of Pittsburgh. Female mice were used for tumor growth and RNA sequencing experiments, while both male and female mice were used for TIL flow cytometry analysis. Cre-YFP (developed in our laboratory 7 ).
Ebi3
L/L-Tom mice were developed in our laboratory and have been previously described 7 .
Il10
L/L (provided by W. Muller (Germany)) 38 and Ebi3 L/L-Tom were crossed to Foxp3
Cre-YFP mice 18 .IL12rb2
-/-) mice were generated as described previously 26 .
Human specimen collection and processing. All specimens were acquired under University of Pittsburgh approved Institutional Review Board protocol, and informed consent was obtained from all patients. All lung tumors were processed to single-cell suspension by a combination of mechanical and enzymatic digestion. For enzymatic digestion, Liberase (Sigma Aldrich) was used at 50 μg ml −1 for 15 minutes at 37 °C in Roswell Park Memorial Institute (RPMI) medium (Lonza) to release TIL. For healthy donor peripheral blood samples, Ficoll Paque Plus (GE Healthcare) was used to separate peripheral blood leukocytes (PBL) and lysis buffer (BD Biosciences) was used to remove red blood cells when necessary.
Staining for EBI3 and IL-10 in human specimens. Lung TIL and healthy donor PBL were incubated in complete RPMI (cRPMI) medium (10% FBS (Atlanta Biologicals), non-essential amino acids (Sigma Aldrich), L-glutamine (Lonza) and penicillin/streptomycin (Corning) and sodium pyruvate (Sigma Aldrich)) with TCR stimulation: plate-bound anti-CD3 (0.5 μg ml Fungal protease-induced allergic airway disease. Mice received seven intranasal challenges with a mixture comprised of a fungal protease derived from Aspergillus oryzae and Ovalbumin, every alternate day for 2 weeks. On day 14, mice were intubated, tracheas were cannulated and flushed with PBS (twice) for isolation of BAL fluid, before isolation of lungs and the draining (mediastinal) and nondraining (inguinal) lymph nodes. Lungs were perfused with 10 ml PBS injected through the right ventricle of the heart using a 20 gauge needle immediately after BAL fluid collection. Harvested lungs were minced into small pieces and digested in 5 ml capped polystyrene tube with 1 mg ml −1 Collagenase D (Roche) in 2 ml PBS for 45 minutes at 37 °C. Digested cell suspension was then processed through a 70 μm cell-strainer and washed with cDMEM. Isolated cells were then used in flow cytometry analysis. Red blood cells were lysed with Gey's solution when appropriate.
Flow cytometry. Single-cell suspensions from mouse or human specimens were stained with live/dead exclusion dye, followed by fluorochrome-conjugated antibodies in the presence of 5% normal mouse serum. TruNuclear transcription factor staining kit (Biolegend) was used for intracellular staining. Flow cytometry data were acquired on BD Fortessa and analyzed by FlowJo (Treestar, Inc.). Pie charts were created using the SPICE program 40 .
Processing and analysis of scRNAseq data. We used Cell Ranger (v.2.0) (10X Genomics) to analyze sequencing data generated from Chromium Single Cell 3' RNAseq libraries 41 . We first ran 'cellranger mkfastq' on the Illumina BCL output folder to generate fastq files. We next generated the UMI count matrix with 'cellranger count' for each library. The data were normalized with R package cellrangerRkit and visualized via t-distributed stochastic neighbor embedding (t-SNE). The diffusion pseudo-time analysis was run with R package Destiny 42, 43 . Briefly, we built a transition matrix for all cells on the basis of their adjacency using a locally scaled Gaussian kernel and determined the diffusion components according to the eigenvectors of the matrix. Then, a new matrix M was generated by removing the first eigenvalue of the original transition matrix and the diffusion pseudo-time was calculated as a distance metric between the rows of M. Finally, we plotted the trajectory lines, which were fitted by the locally weighted scatterplot smoothing (LOESS) regression using the previously calculated values. For the differential expression analyses between the IL-10 and Ebi3 gene-expressing cells in lymph node and tumor T reg cells, we used the 'sseq' method from the standard R package cellrangerRkit. Additionally, top expressed genes from differential expression analysis were determined by performing the two-sided Negative Binomial Exact test 44 and the P values were adjusted to control the FDR 45 .
RNAseq profiling and data analysis. T reg cell fractions and NDLN Foxp3-YFP CD4 + T eff control were FACS sorted from day 14 B16 tumor-bearing Il10
Cre-YFP mice. CD8 + T cell subsets were FACS sorted from day 14 B16-bearing wild-type control and T reg cell cytokine-deficient mice.
Each cell fraction was double-sorted to ensure high purity (>95%) and directly lysed using the Clontech SMART-Seq v.4 (T reg cells) or v.3 (CD8) kit for complimentary DNA synthesis. Libraries were prepared using Nextera XT DNA Library Preparation kit (Illumina), normalized at 2 nM using Tris-HCl (10 mM, pH 8.5) with 0.1% Tween20, diluted and denatured to a final concentration of 1.8 nM. Cluster generation and 75 base pair paired-end dual-indexed sequencing were performed on Illumina NextSeq 500 system. RNAseq data were aligned to the mm10 genome using the STAR aligner 46 and quantified against the Refseq gene models 47 using featureCounts 48 . The number of uniquely aligned reads ranged from 10 to 12 million. The raw data counts were processed for differential expression using the 'voom' function 49 in the limma R package 50, 51 with the robust model option. Gene set enrichment testing was performed using the 'RankSumTestWithCorrelation' function in the limma R package, which automatically corrects enrichment statistic inflation due to correlation among genes. We used the GSEA-style enrichment score for visualization of pathway enrichment results 52 . We defined the tumor-specific exhaustion signature to be the set of genes that are overexpressed in the PD-1 hi state (both DP and SP) when compared to PD-1 neg state in Foxp3 Cre-YFP mice at a fold change of four and q value FDR of 0.05. Tumorexhaustion signature was aligned with the chronic LCMV exhaustion profile dataset (Gene Expression Omnibus (GEO) accession number: GSE9650) 28 . The CXCR5 + PD-1-responsive CD8 + T cell signature was derived from GEO accession number: GSE84105 (ref. 30 ).
In vitro microsuppression assay. Sorted T reg cell subpopulations from NDLN and B16 tumors were co-cultured with CellTrace Violet (Life Technologies)-labeled CD4 + Foxp3 -responder T cells (T responders ) in the presence of mitomycin-C-treated TCRβ-depleted splenocytes and anti-CD3ε (1 μg ml Cre-YFP mice. DNA was purified using a QIAamp DNA Micro Kit (QIAGEN), and TCRbetaenriched library was generated with TCRbeta immunoSeq (Adaptive Biotechnologies), following the manufacturer's protocol. Cluster generation and sequencing were performed on the Illumina high output NextSeq 500 system. The data were analyzed using an immunoSeq Analyzer (Adaptive Biotechnologies). 
Software and code
Policy information about availability of computer code
Data collection
For flow cytometry data collection, we utilized BD LSRIIFORTESSA with DIVA software, and exported the data in fcs3.0 version. RNAseq data collection was performed according to the instruction of illumina on NextSeq500 system. For single cell RNAseq, cDNA library preparation was performed using and following the instruction of the 10X Genomics platform and the sequencing data was collected on NextSeq500 system.
Data analysis
For flow cytometry data analysis, we utilized FlowJo (version 10 (most recently updated to 10.5.3 for Mac)) and numerical data exported to Excel sheet were further analyzed by using GraphPad Prism (version 7 and 8 for Mac) to generate graphical representation and for ANOVA statistical analysis. Furthermore, comma separated value (csv) files exported from Excel sheet upon multi-parameter flow cytometry analysis was import to SPICE program (NIH-NIAID) to generate SPICE plots to visually represent the expression level and coexpression combination of multiple inhibitory receptors analyzed. For Treg in vitro suppression assay, FlowJo legacy version 9 for Mac was used in order to utilize the proliferation analysis module.
RNASeq data were aligned to the mm10 genome using the STAR aligner,and quantified against the Refseq gene models using featureCounts. The raw data counts were processed for differential expression using the "voom" function in the limma R package, with the robust model option. Gene set enrichment testing was performed using the "RankSumWithCorrelation" function in the limma R package, which automatically corrects enrichment statistic inflation due to correlation among genes. We used the GSEA-style enrichment score for visualization of pathway enrichment results.
For single cell RNAseq data analysis, we used Cell Ranger (v2.0) (10X Genomics) to analyze sequencing data generated from Chromium Single Cell 3' RNA-seq libraries40. We first ran "cellranger mkfastq" on the Illumina BCL output folder to generate fastq files. We next generated the UMI count matrix with "cellranger count" for each library. The data were normalized with R package cellrangerRkit and visualized via t-distributed stochastic neighbor embedding (t-SNE). The diffusion pseudo-time analysis was run with R package Destiny41,42. Briefly, we built a transition matrix for all cells based on their adjacency using a locally-scaled Gaussian kernel and determined the diffusion components according to the eigenvectors of the matrix. Then, a new matrix M was generated by removing the first eigenvalue of the original transition matrix and the diffusion pseudo-time was calculated as a distance metric between the rows of Recruitment Subjects were first approached by their treating surgeon, radiologist, pulmonologist or medical oncologist who determined their willingness to participate in research studies. If a patient was willing to be a subject, a complete explanation of the research was given to them by a research coordinator and informed consent was obtained and documented. The goal of the research study and its methods was discussed and all pages of the informed consent document was reviewed with the subject and any questions answered. Once there was a thorough understanding by the subject of the contents of the consent form and a reiteration of the nature of the research study, the patient was asked to sign and date the form. A signed and dated copy, including the signature of the person obtaining the consent was given to the patient at the time consent was obtained, and the subject was again informed that participation would not influence medical care and that withdrawal was possible at any time.
There were no self-selection bias or other biases that would have impacted results as the research group received all patient samples in a de-identified manner.
Ethics oversight
All specimens were acquired under University of Pittsburgh approved Institutional Review Board (IRB) protocol, and informed consent was obtained from all patients.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
For mouse specimen processing: To obtain single cell suspension samples for flow cytometry analysis, the samples were processed as following: Spleens or lymph nodes were processed through 40μm cell strainers to obtain single suspension. Tumor samples were first mechanically minced into small pieces with scissors, followed by enzymatic digestion with Collagenase IV and Dispase in complete RPMI1640 medium for 30 minutes. Digested tumors were then processed through 70μm cell strainer. Red blood cells in spleens and tumors were lysed with ammonium chloride solution. All the samples were first stained with live/dead discrimination dye in PBS prior to antigen staining in FACS buffer containing 5% FBS and 5% normal mouse serum. For human specimen processing: All specimens were acquired under a University of Pittsburgh approved and exempt Institutional Review Board (IRB) protocol with a non human subjects designation as all specimens were collected in a blinded fashion, and informed consent was obtained from all patients and healthy donors. We collected peripheral blood from healthy donor to obtain PBL samples, and human tumor samples were collected from patients with non-small cell lung carcinoma (NSCLC). For enzymatic digestion, Liberase (Sigma Aldrich) was used at 50 μg/mL for 15 minutes at 37°C in RPMI medium (Lonza) to release tumor infiltrating lymphocytes (TIL). For healthy donor peripheral blood samples, Ficoll Paque Plus (GE Healthcare) was used to separate peripheral blood leukocytes (PBL) and lysis buffer (BD biosciences) was used to remove red blood cells when necessary. Lung TIL and HD PBL were incubated in complete RPMI medium (10% FBS (Atlanta biologicals), non-essential amino acids (Sigma Aldrich), L-glutamine (Lonza) and penicillin/streptomycin (Corning) and sodium pyruvate (Sigma Aldrich)) with TCR stimulation: plate-bound anti-CD3 (0.5 μg/mL, Invitrogen, clone: OKT3) and soluble anti-CD28 (1 μg/mL Invitrogen, clone: CD28.2) and 200U/ ml rhIL-2 overnight followed by four hours of stimulation with PMA/ionomycin and GolgiStop. The cells were then harvested and stained with surface antibodies (CD3, CD4, CD8, CD25) and viability dye. A fixation/permeabilization kit (eBiosciences) was used nature research | reporting summary
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according to manufacturer's protocol, followed by intracellular staining.
Instrument
BD LSRFORTESSA for flow cytometry analysis and BD Aria sorter for cell purification.
Software
FlowJo was used to gate the target populations, and Microsoft Excel, Graphpad Prism, and SPICE were used for further analyses.
Cell population abundance For RNAseq experiments where cells were purified by FACS-sorting, we ensured the purity of the sorted samples by sequential double-sorting. The purity was determined by re-analyzing the double-sorted samples on the same instrument (BD FACSAria). All the fractionated subpopulations used for RNAseq experiments were uniformly 500 cells per sample, which was directly sorted into 96-well plate containing lysis buffer for cDNA synthesis purpose.
For adoptive transfer experiments, we purified the target cells by streptavidin-magnetic bead negative selection. The purity of the isolated cells was determined on BD LSRFORTESSA prior to transfer.
Gating strategy
For all the experiments involving flow cytometry (either for analyzing or FACS-sorting), the following gating strategy was applied to eliminate non-specifically stained cells. First, lymphocyte gate was applied on the SSC-A/FSC-A window. The gating size was determined by comparing the lymphocyte cluster from lymph node samples to the matched tumor samples in order to adjust for the blasted tumor infiltrating lymphocyte cell size. Subsequently, sequential singlet/doublet discrimination was applied via SSC-W/SSC-H and FSC-W/FSC-H. From the selected singlets, dead cells were discriminated out by gating on live/dead dye negative population. For our study is focused on tumor infiltrating T cells, we have subsequently gated on TCRb+CD4+CD8-or TCRb+CD8+CD4-for further analysis. In order to set the gating for positive populations, we used unstained samples and also stained lymph node samples for inhibitory receptor staining as lymph node counterparts do not express them compared to tumor infiltrating lymphocytes.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
